Comparison of the effectiveness of the Montreal Cognitive Assessment 7.2 and the Mini-Mental State Examination in the detection of mild neurocognitive disorder in people over 60 years of age. Preliminary study.

Sokołowska, Natalia; Sokołowski, Remigiusz; Polak-Szabela, Anna; Mazur, Ewelina; Podhorecka, Marta; Kędziora–Kornatowska, Kornelia

doi:10.12740/pp/68611

Cited by 9 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the MMSE is the commonly used scale for evaluating cognitive function, it is claimed to be imprecise for detecting early and mild cognition impairment. 32 In conclusion, our long-term follow-up analysis of a single-center cohort of the MT103-104 phase 1 trial revealed that blinatumomab is a highly effective CD19-targeting bispecific antibody capable of inducing durable remissions in heavily pretreated patients with advanced-stage R/R B-NHL. This also applies to lymphoma regardless of tumor burden.…”

Section: Discussionmentioning

confidence: 74%

Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab

et al. 2019

View full text Add to dashboard Cite

Blinatumomab, the first-in-class CD3/CD19 bispecific T-cell engager antibody construct, has recently been approved for treating patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia. However, the clinical proof of concept of blinatumomab efficacy was initially demonstrated in patients with R/R B-cell non-Hodgkin lymphoma (B-NHL) in the MT103-104 phase 1 dose-escalation and expansion trial (NCT00274742), which defined 60 µg/m2 per day as the maximum tolerated dose (MTD). The clinically most relevant adverse effects were neurologic symptoms and cytokine release syndrome. Currently, there are no data on long-term outcomes and toxicity for B-NHL patients receiving blinatumomab treatment, so we performed a single-center, long-term follow-up analysis of 38 patients who participated in the MT103-104 phase 1 trial. We found no evidence for long-term toxicities, especially no blinatumomab-induced neurocognitive impairments. For the entire study population, the median overall survival (OS) was 4.6 years. Remarkably, patients who had received ≥60 µg/m2 per day and responded to blinatumomab achieved a median OS of 7.7 years. Of note, 6 of the surviving patients treated at the MTD have been treatment-free for more than 7 years. In contrast, patients who were treated at dose levels below the MTD had a median OS of only 1.1 years. These results indicate that 60 µg/m2 per day seems to represent the targeted dose level of blinatumomab required for durable remission in R/R B-NHL. Here, we provide the first clinical evidence that blinatumomab lacks long-term toxicity and has the potential to induce sustained remissions in patients with R/R B-NHL.

show abstract

Section: Discussionmentioning

confidence: 74%

Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Information of each study including the objective, clinical characteristics of the sample, main outcomes, and results is presented in Table 1. The Mini-Mental State Examination [49] was the most widely used tool to determine the severity of the NCDs with a wide range in the scores (10–30), followed by the Montreal Cognitive Assessment [50] with scores ranging from 18 to 30 points. Outcome measures include traditional neuropsychological tests (e.g.…”

Section: Resultsmentioning

confidence: 99%

A systematic review of the use of virtual reality and its effects on cognition in individuals with neurocognitive disorders

Moreno

Wall

Thangavelu

et al. 2019

A&D Transl Res & Clin Interv

104

View full text Add to dashboard Cite

Introduction Virtual reality (VR) interventions are increasingly used in individuals with brain injuries. The objective of this study was to determine the effects of VR on overall cognitive functioning in individuals with neurocognitive disorders (NCDs). Methods Using Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, a systematic review of the published literature on immersive and nonimmersive VR technologies targeting cognition in minor and major NCDs was conducted: (PROSPERO registration number: CRD42019121953). Results A total of 22 studies were included in the review, for an aggregated sample of 564 individuals with NCDs. Most of the studies were conducted on patients who had stroke (27.3%), followed by mild cognitive impairment (22.7%) and Alzheimer's disease (13.6%). VR interventions used for cognitive rehabilitation suggested to improve cognition (e.g. memory, dual tasking, and visual attention), and secondarily to psychological functioning (e.g. reduction of anxiety, higher levels of well‐being, and increased use of coping strategies). Conclusion VR interventions are useful to improve cognition and psychological symptoms in NCDs.

show abstract

“…The reliability of the Polish version of the MoCA 7.2 was analyzed by Sokolowska and colleagues, who demonstrated that the MoCA detects MCI with a sensitivity of 89.5% and a specificity of 74.1 at a cutoff point of 24 or below. In this study, the recommended cutoff point for the MoCA resulted in a sensitivity of 43.3% [ 43 ]. Identification of MCI was based on the DSM-5 criteria [ 73 ].…”

Section: Montreal Cognitive Assessment (Moca)mentioning

confidence: 99%

Screening for Mild Cognitive Impairment in the Preoperative Setting: A Narrative Review

et al. 2022

View full text Add to dashboard Cite

Cognitive impairment predisposes patients to the development of delirium and postoperative cognitive dysfunction. In particular, in older patients, the adverse sequelae of cognitive decline in the perioperative period may contribute to adverse outcomes after surgical procedures. Subtle signs of cognitive impairment are often not previously diagnosed. Therefore, the aim of this review is to describe the available cognitive screeners suitable for preoperative screening and their psychometric properties for identifying mild cognitive impairment, as preoperative workup may improve perioperative care for patients at risk for postoperative cognitive dysfunction. Electronic systematic and snowball searches of PubMed, PsycInfo, ClinicalKey, and ScienceDirect were conducted for the period 2015–2020. Major inclusion criteria for articles included those that discussed a screener that included the cognitive domain ‘memory’, that had a duration time of less than 15 min, and that reported sensitivity and specificity to detect mild cognitive impairment. Studies about informant-based screeners were excluded. We provided an overview of the characteristics of the cognitive screener, such as interrater and test-retest reliability correlations, sensitivity and specificity for mild cognitive impairment and cognitive impairment, and duration of the screener and cutoff points. Of the 4775 identified titles, 3222 were excluded from further analysis because they were published prior to 2015. One thousand four hundred and forty-eight titles did not fulfill the inclusion criteria. All abstracts of 52 studies on 45 screeners were examined of which 10 met the inclusion criteria. For these 10 screeners, a further snowball search was performed to obtain related studies, resulting in 20 articles. Screeners included in this review were the Mini-Cog, MoCA, O3DY, AD8, SAGE, SLUMS, TICS(-M), QMCI, MMSE2, and Mini-ACE. The sensitivity and specificity range to detect MCI in an older population is the highest for the MoCA, with a sensitivity range of 81–93% and a specificity range of 74–89%. The MoCA, with the highest combination of sensitivity and specificity, is a feasible and valid routine screening of pre-surgical cognitive function. This warrants further implementation and validation studies in surgical pathways with a large proportion of older patients.

show abstract

Comparison of the effectiveness of the Montreal Cognitive Assessment 7.2 and the Mini-Mental State Examination in the detection of mild neurocognitive disorder in people over 60 years of age. Preliminary study.

Cited by 9 publications

References 30 publications

Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab

Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab

A systematic review of the use of virtual reality and its effects on cognition in individuals with neurocognitive disorders

Screening for Mild Cognitive Impairment in the Preoperative Setting: A Narrative Review

Contact Info

Product

Resources

About